Corneal Diseases
Santen Inc. is engaged in clinical research focused on Fuchs endothelial corneal dystrophy, a degenerative disorder of the corneal endothelium that affects vision and corneal clarity.
- Fuchs endothelial corneal dystrophy
- Corneal endothelial dysfunction
- Ocular surface and anterior segment disease
The sponsor’s research activity reflects a therapeutic interest in conditions that impair corneal function and visual performance.
Ophthalmic Therapeutics
Its clinical portfolio includes investigation of ophthalmic suspension therapies intended for the treatment of corneal disease, with attention to local eye-targeted intervention.
- Topical ophthalmic treatment
- Corneal-targeted therapy
- Vision-related disease management
Research in this area centers on therapies designed for direct ocular administration in patients with chronic corneal pathology.
Clinical Safety and Efficacy in Eye Disease
The sponsor is active in evaluating both efficacy and safety outcomes for ophthalmic treatment in individuals with corneal endothelial disease.
- Ocular safety
- Treatment effectiveness
- Patient tolerance in eye disorders
This area supports development of therapies for chronic conditions where preservation of corneal structure and visual function is central.
